secwatch.observer — SEC 8-K summary
======================================

Issuer:     Praxis Precision Medicines, Inc. (PRAX)
CIK:        0001689548
Form:       8-K
Filed at:   2026-04-14T23:59:59+00:00
Accession:  0001689548-26-000033
Event type: regulatory
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Praxis Precision: FDA accepts NDA for ulixacaltamide in essential tremor; PDUFA Jan 29, 2027
--------------------------------------------------------------------------------

- FDA accepted NDA for ulixacaltamide HCl to treat essential tremor in adults; PDUFA target action date January 29, 2027.
- No advisory committee meeting will be held for the ulixacaltamide NDA review.
- The NDA seeks approval for a novel small-molecule therapy for a common movement disorder.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1689548/000168954826000033/0001689548-26-000033-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1689548/000168954826000033/prax-20260414.htm
  HTML page:      https://secwatch.observer/filing/0001689548-26-000033

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer